Rating Change
HC Wainwright & Co. analysts reiterated a Buy rating on Gossamer Bio, Inc. (NASDAQ:GOSS) on June 25, 2026.
reiterateNASDAQ:GOSS
HC Wainwright & Co. Reiterates Buy Rating on Gossamer Bio, Inc. (GOSS)
Rating Change HC Wainwright & Co. analysts reiterated a Buy rating on Gossamer Bio, Inc. (NASDAQ:GOSS) on June 25, 2026.
Market Context
Gossamer Bio, Inc. operates in the Healthcare sector. The stock currently trades at $0.17 with a market capitalization of $824.3M. The stock has declined 87.7% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Gossamer Bio, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Gossamer Bio, Inc.
Among the 10 most recent ratings: 5 Buy, 3 Hold, 2 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 25, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 26, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 19, 2026 | Barclays | Underweight | N/A |
| Mar 23, 2026 | Cantor Fitzgerald | Neutral | N/A |
| Mar 06, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View GOSS Stock Page
Frequently Asked Questions
What does a Buy rating mean for GOSS?
A Buy rating from HC Wainwright & Co. reflects the analyst's outlook on Gossamer Bio, Inc. (NASDAQ:GOSS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the GOSS forecast page.